MedElevator
Войти в исследования Journal of clinical gastroenterology · 2026
Association of NAFLD and Cardiovascular Events: A Systematic Review and Meta-analysis.
Систематический обзорСтатьяМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bhatia Mannat K, Garg Archit, Ali Junaid, Santos Allan, Bhatia Mehar K, Singh Birgurman, Bassi Mehak, Broder Arkady, Adler Douglas G
Аннотация
BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is increasingly recognized as a risk factor for cardiovascular disease (CVD) but the association remains unclear. This systematic review and meta-analysis aimed to quantify these associations.
METHODOLOGY: We searched multiple databases for articles reporting CVD outcomes in MAFLD and conducted meta-analysis.
RESULTS: A total of 49 studies encompassing 1,553,770 individuals with MAFLD were included. MAFLD without advanced fibrosis was significantly associated with increased risks of fatal (HR 1.46, 95% CI 1.23-1.73; P <0.01), nonfatal (HR 1.54, CI 1.29-1.84; P <0.01), and combined CVD events (HR 1.60; CI 1.30-1.97; P <0.01). MAFLD with advanced fibrosis was significantly associated with combined CVD events (HR 1.79, CI 1.09-2.92; P <0.01) but not with fatal CVD events (HR 1.23, CI 1.00-1.52; P =0.06) or nonfatal CVD events (HR 1.08, CI 0.82-1.42; P =0.582).
CONCLUSION: MAFLD, even without advanced fibrosis, is an independent risk factor for CVD. The risk is amplified with advanced fibrosis, particularly for combined CVD events.
METHODOLOGY: We searched multiple databases for articles reporting CVD outcomes in MAFLD and conducted meta-analysis.
RESULTS: A total of 49 studies encompassing 1,553,770 individuals with MAFLD were included. MAFLD without advanced fibrosis was significantly associated with increased risks of fatal (HR 1.46, 95% CI 1.23-1.73; P <0.01), nonfatal (HR 1.54, CI 1.29-1.84; P <0.01), and combined CVD events (HR 1.60; CI 1.30-1.97; P <0.01). MAFLD with advanced fibrosis was significantly associated with combined CVD events (HR 1.79, CI 1.09-2.92; P <0.01) but not with fatal CVD events (HR 1.23, CI 1.00-1.52; P =0.06) or nonfatal CVD events (HR 1.08, CI 0.82-1.42; P =0.582).
CONCLUSION: MAFLD, even without advanced fibrosis, is an independent risk factor for CVD. The risk is amplified with advanced fibrosis, particularly for combined CVD events.